BioXcel Therapeutics, Inc.
About BioXcel Therapeutics, Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $642.0K
- Net income
- -$69.9M
- Total assets
- $44.9M
- Market cap
- $34.1M
- Gross margin
- 74.5%
- Operating margin
- -7860.0%
- Net margin
- -10887.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $642.0K
- Cost of revenue
- $164.0K
- Gross profit
- $478.0K
- Operating expenses
- $50.9M
- Operating income
- -$50.5M
- Income tax
- $0
- Net income
- -$69.9M
- EPS (basic)
- $-5.73
- EPS (diluted)
- $-5.73
Balance sheet
- Total assets
- $44.9M
- Current assets
- $44.7M
- Total liabilities
- $140.4M
- Current liabilities
- $53.9M
- Shareholders’ equity
- -$95.5M
Cash flow
- Operating cash flow
- -$57.6M
- Investing cash flow
- $1.1M
- Financing cash flow
- $56.5M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $34.1M
- EPS (diluted)
- $-5.73
- Shares outstanding
- 31.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 8, 2018
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $69.9M in FY2025.
- Gross margin of 74.5%, net margin -10887.4%.
- Trading 84% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review BioXcel Therapeutics, Inc..
Write a review
News about BioXcel Therapeutics, Inc.
News & sentiment via Polygon.io
